Nanobiotix (NBTX) news
Recent news
French Pharma shares Genfit, Nanobiotix, Valneva down between 4.8% and 6.2%
On Monday, several French pharmaceutical stocks experienced declines, with Genfit S.A. (GNFT.PA), Nanobiotix, and Valneva all posting losses in the range of 4.8% to 6.2%. The drop comes amid broader market volatility and sector-specific pressures affecting biotech and pharmaceutical firms.…
AInvest Wire · 7d agoNanobiotix names Arnd Christ as CFO
AInvest Wire · Oct 1, 2026Nanobiotix provides first half 2026 operational and financial update
Nanobiotix, a late-clinical stage biotechnology company, provided an operational and financial update for the first half of 2026, highlighting key developments in its clinical and financial activities. The company completed a follow-on offering in May 2026, generating approximately €86.1 million in…
AInvest Wire · Sep 24, 2026Nanobiotix SA: Guggenheim assumes coverage with buy rating; target price $64
AInvest Wire · Sep 15, 2026Nanobiotix - At 12-month follow-up (Aug 2026), one-year locoregional control 79%, LPFS 61%, OS 70%
Nanobiotix has reported one-year clinical outcomes from an ongoing study as of August 2026. At the 12-month follow-up, the locoregional control rate was observed at 79%, with a locoregional progression-free survival (LPFS) rate of 61% and an overall survival (OS) rate of 70%. These metrics provide…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.